UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month ofMarch, 2019
Commission File Number:333-229744
EMERALD HEALTH THERAPEUTICS, INC.
(Translation of registrant's name into English)
210 – 800 West Pender Street
Vancouver, British Columbia V6C 1J8
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
¨ Form 20-F x Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):¨
INCORPORATION BY REFERENCE
Exhibit 99.1 to this Form 6-K of Emerald Health Therapeutics, Inc. (the “Company”) ishereby incorporated by reference as an exhibit to the Registration Statement on Form F-10 (File No. 333-229744) of the Company, as amended or supplemented.
EXHIBITS
99.1 Equity Distribution Agreement dated March 27, 2019
99.2 News Release dated March 28, 2019
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Emerald Health Therapeutics, Inc. | ||
| (Registrant) | ||
| Date: March 28, 2019 | By: | /s/ Dr. Avtar Dhillon |
| Name: | Dr. Avtar Dhillon | |
| Title: | Executive Chairman | |
